Business context and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the quarter and nine months ended March 31, 2021 (fiscal Q3 2021), not a filing for “Lite Strategy, Inc.” or 2019 Q3 as stated in the request metadata. The summary below reflects the filing text.
MEI Pharma is a clinical-stage oncology company with four clinical-stage candidates: zandelisib, voruciclib, ME-344 and pracinostat. Revenue is principally collaboration and license-related, rather than product sales. Dollar figures below are in millions unless otherwise noted.
Key financial metrics
| Metric | Three months ended Mar. 31, 2021 | Three months ended Mar. 31, 2020 | Nine months ended Mar. 31, 2021 | Nine months ended Mar. 31, 2020 |
|---|---|---|---|---|
| Revenue | $2.4 | $1.2 | $15.4 | $3.4 |
| Operating expenses | $24.5 | $13.7 | $72.3 | $40.6 |
| Loss from operations | $(22.1) | $(12.4) | $(56.9) | $(37.2) |
| Net loss | $(31.3) | $(4.3) | $(44.9) | $(27.5) |
| Net loss per share, basic | $(0.28) | $(0.04) | $(0.40) | $(0.32) |
| Net cash used in operating activities | Not presented | Not presented | $(20.7) | $(34.9) |
- Revenue rose substantially year over year, primarily from recognition of KKC collaboration revenue as MEI performed development services. Nine-month KKC revenue was $15.0 million; Helsinn revenue was $0.4 million.
- Research and development expense was $53.1 million for the nine months, up from $26.2 million, mainly due to increased zandelisib trial activity and Phase 3 start-up, manufacturing and personnel costs. General and administrative expense rose to $17.8 million from $12.2 million.
- Other income and expense included a non-cash $9.3 million warrant-liability loss in the quarter, compared with a $7.7 million gain in the prior-year quarter. For the nine months, the warrant-liability change was an $11.0 million gain. These fair-value movements materially affected net loss.
- At March 31, 2021, cash and cash equivalents were $9.7 million and short-term investments were $154.9 million, totaling $164.6 million, versus $182.6 million at June 30, 2020. Short-term investments were U.S. government securities.
- Total assets were $186.1 million and total liabilities $141.2 million; stockholders’ equity was $45.0 million. Liabilities included $29.4 million of warrant liability, $89.9 million of deferred revenue (current and long-term), and $8.5 million of operating lease liability. The filing does not report conventional borrowings or interest-bearing debt.
- Operating cash use fell to $20.7 million from $34.9 million, partly due to collection of a $20.4 million Japanese tax-withholding receivable in October 2020. Financing provided $3.4 million, primarily from ATM stock sales; investing provided $14.7 million, mainly reflecting net short-term investment maturities.
Material changes versus prior comparable period
- Nine-month net loss increased to $44.9 million from $27.5 million as operating expenses grew faster than collaboration revenue.
- Nine-month revenue increased to $15.4 million from $3.4 million, principally due to the KKC agreement and increased development activity.
- The company sold 958,083 shares under its prior ATM program for $3.1 million net during the nine-month period. A new ATM agreement permits up to $60.0 million of additional sales; $175.7 million remained available under the shelf registration statement at period-end.
- MEI recognized an $8.7 million operating lease right-of-use asset and corresponding liability when its San Diego office lease commenced in July 2020. The lease runs through March 2028.
- The pracinostat Phase 3 AML study was discontinued by Helsinn in July 2020 after an interim futility analysis; Helsinn withdrew the related breakthrough therapy designation. The pracinostat MDS Phase 2 study was complete, and MEI reported no remaining Helsinn performance obligations or future revenue from that agreement.
Guidance, outlook, commentary and risks
- Management expects continuing operating losses and negative operating cash flows, and anticipates R&D expense will increase. It believed the $164.6 million of cash and short-term investments would fund obligations and planned operations for at least 12 months and into fiscal 2022 and beyond; future capital transactions may nevertheless be needed, with no assurance of access to financing.
- Zandelisib’s Phase 2 TIDAL trial is intended to support potential FDA accelerated-approval applications. FL primary-population enrollment was completed in April 2021; topline data were expected in calendar Q4 2021. The filing also described plans to initiate the Phase 3 COASTAL study around mid-2021. These are forward-looking plans, not reported outcomes.
- COVID-19 was continuing to affect trial timelines and enrollment rates. Potential risks included enrollment delays, patient withdrawals, site disruption, supply constraints, and impacts on data integrity or regulatory review.
- Clinical and regulatory outcomes are uncertain; candidates may fail to demonstrate efficacy or safety, and approvals or commercialization may not occur. The company also cited financing needs, dependence on collaborators and third-party manufacturers, competition, and intellectual-property and regulatory risks.
- Potential milestone obligations include up to $179 million under the Presage agreement and up to $74.5 million under the S*Bio agreement, plus other contingent royalties or payments. No amounts were accrued because milestones had not been achieved.
- The securities class action and related stockholder derivative litigation concerning pracinostat allegations were voluntarily dismissed without prejudice in February 2021. Management reported disclosure controls were effective and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied text is MEI Pharma’s March 31, 2021 Form 10-Q, not Lite Strategy’s 2019 Q3 filing.
- Check subsequent TIDAL trial results, regulatory interactions and whether the expected Q4 2021 topline timing and planned COASTAL launch occurred.
- Assess cash runway against actual R&D spending, trial commitments and future financing; the period’s operating cash flow benefited from a one-time tax-receivable collection.
- Review the warrant-liability valuation and potential dilution: 16.1 million warrants were outstanding at $2.54 per share, expiring in May 2023, and the liability is Level 3 fair value.
- Track KKC collaboration revenue, cost-sharing estimates, deferred revenue recognition, and whether collaborators meet their obligations.
- Review the complete filing and later disclosures for clinical, COVID-19, contingent-payment and financing developments; this summary is based only on the supplied text.